ASSERTIO HOLDINGS INC (ASRT) Stock Price & Overview

NASDAQ:ASRTUS04546C3043

Current stock price

18.02 USD
0 (0%)
Last:

The current stock price of ASRT is 18.02 USD. Today ASRT is down by 0%. In the past month the price increased by 53.1%. In the past year, price increased by 96.81%.

ASRT Key Statistics

52-Week Range8.5515 - 20.45
Current ASRT stock price positioned within its 52-week range.
1-Month Range11.28 - 20.45
Current ASRT stock price positioned within its 1-month range.
Market Cap
116.229M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-3.21
Dividend Yield
N/A

ASRT Stock Performance

Today
0%
1 Week
-3.12%
1 Month
+53.10%
3 Months
+56.97%
Longer-term
6 Months +50.13%
1 Year +96.81%
2 Years +35.73%
3 Years -78.20%
5 Years -45.40%
10 Years N/A

ASRT Stock Chart

ASSERTIO HOLDINGS INC / ASRT Daily stock chart

ASRT Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ASRT. When comparing the yearly performance of all stocks, ASRT is one of the better performing stocks in the market, outperforming 93.68% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ASRT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ASRT. ASRT has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ASRT Earnings

On March 16, 2026 ASRT reported an EPS of -1.86 and a revenue of 13.54M. The company beat EPS expectations (32.71% surprise) and missed revenue expectations (-20.15% surprise).

Next Earnings DateMay 11, 2026
Last Earnings DateMar 16, 2026
PeriodQ4 / 2025
EPS Reported-$1.86
Revenue Reported13.542M
EPS Surprise 32.71%
Revenue Surprise -20.15%

ASRT Forecast & Estimates

10 analysts have analysed ASRT and the average price target is 39.02 USD. This implies a price increase of 116.51% is expected in the next year compared to the current price of 18.02.

For the next year, analysts expect an EPS growth of 64.49% and a revenue growth 4.25% for ASRT


Analysts
Analysts82
Price Target39.02 (116.54%)
EPS Next Y64.49%
Revenue Next Year4.25%

ASRT Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

ASRT Financial Highlights

Over the last trailing twelve months ASRT reported a non-GAAP Earnings per Share(EPS) of -3.21. The EPS increased by 6.96% compared to the year before.


Income Statements
Revenue(TTM)118.71M
Net Income(TTM)-30.38M
Industry RankSector Rank
PM (TTM) N/A
ROA -11.38%
ROE -32.33%
Debt/Equity 0.42
Chartmill High Growth Momentum
EPS Q2Q%-12.73%
Sales Q2Q%-57.92%
EPS 1Y (TTM)6.96%
Revenue 1Y (TTM)-5%

ASRT Ownership

Ownership
Inst Owners33.2%
Shares6.45M
Float6.31M
Ins Owners1.24%
Short Float %4.78%
Short Ratio2.6

About ASRT

Company Profile

ASRT logo image Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.

Company Info

IPO: 1997-02-12

ASSERTIO HOLDINGS INC

100 S. Saunders Road, Suite 300

Lake Forest ILLINOIS 60045 US

CEO: Daniel A. Peisert

Employees: 58

ASRT Company Website

ASRT Investor Relations

Phone: 12244197106

ASSERTIO HOLDINGS INC / ASRT FAQ

Can you describe the business of ASSERTIO HOLDINGS INC?

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.


What is the stock price of ASSERTIO HOLDINGS INC today?

The current stock price of ASRT is 18.02 USD.


What is the dividend status of ASSERTIO HOLDINGS INC?

ASRT does not pay a dividend.


How is the ChartMill rating for ASSERTIO HOLDINGS INC?

ASRT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the analyst forecast for ASRT stock?

10 analysts have analysed ASRT and the average price target is 39.02 USD. This implies a price increase of 116.51% is expected in the next year compared to the current price of 18.02.


What is the market capitalization of ASRT stock?

ASSERTIO HOLDINGS INC (ASRT) has a market capitalization of 116.23M USD. This makes ASRT a Micro Cap stock.


What is the Short Interest ratio of ASSERTIO HOLDINGS INC (ASRT) stock?

The outstanding short interest for ASSERTIO HOLDINGS INC (ASRT) is 4.78% of its float.